Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
about
Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.Human brown adipose tissue as a target for obesity management; beyond cold-induced thermogenesis.Clinical implications of underactive bladder.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged ≥75 Years: Analysis of a Japanese Post-Marketing Study.
P2860
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@en
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@nl
type
label
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@en
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@nl
prefLabel
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@en
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@nl
P2860
P1476
Mirabegron for the treatment o ...... and patients with OAB in Asia.
@en
P2093
Christopher R Chapple
Emad Siddiqui
P2860
P304
P356
10.1080/17512433.2017.1275570
P407
P577
2016-12-21T00:00:00Z